Lower Risk of Chronic Health Conditions: Reducing body fat has been linked to lower risks of cardiovascular disease, diabetes, and joint strain, among other health benefits
Cardiovascular Outcome Data Tirzepatide has the SURMOUNT-MMO trial underway, with results expected in 2026 that will directly measure cardiovascular event reduction
Both groups lost a similar amount of weight about 13% of body weight over 6 months
To understand typical reactions, patients can check out our guide about the most common Tirzepatide side effects, like digestion changes and initial adjustments: Easier Dose Adjustment Increasing the dose of Tirzepatide is needed to get the full benefits of treatment
In a randomized clinical trial, tesamorelin reduced visceral adipose tissue and liver fat in HIV-infected patients (Stanley et al., JAMA, 2014), and its Phase 3 program (Falutz et al.) established the visceral-fat effect that underpins its FDA approval